Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists
Michelson, Alan D. ; Furman, Mark I. ; Goldschmidt-Clermont, P. ; Mascelli, Mary Ann ; Hendrix, Craig ; Coleman, Lindsay ; Hamlington, Jeannette ; Barnard, Marc R. ; Kickler, Thomas ; Christie, Douglas J. ... show 2 more
Citations
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Keywords
Adult
Amino Acid Substitution
Antibodies, Monoclonal
Aspirin
Blood Platelets
Cell Membrane
Dose-Response Relationship, Drug
Female
Fibrinogen
Gene Dosage
Genotype
Humans
Immunoglobulin Fab Fragments
Male
P-Selectin
Platelet Aggregation
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Polymorphism, Genetic
Reference Values
Hematology
Oncology
Pediatrics
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
BACKGROUND: Both inherited predisposition and platelet hyperreactivity have been associated with ischemic coronary events, but mechanisms that support genetic differences among platelets from different subjects are generally lacking. Associations between the platelet Pl(A2) polymorphism of GP IIIa and coronary syndromes raise the question as to whether this inherited variation may contribute to platelet hyperreactivity.
METHODS AND RESULTS: In this study, we characterized functional parameters in platelets from healthy donors with the Pl(A) (HPA-1) polymorphism, a Leu (Pl(A1)) to Pro (Pl(A2)) substitution at position 33 of the GP IIIa subunit of the platelet GP IIb/IIIa receptor (integrin alpha(IIb)beta(3)). We studied 56 normal donors (20 Pl(A1,A1), 20 Pl(A1,A2), and 16 Pl(A2,A2)). Compared with Pl(A1,A1) platelets, Pl(A2)-positive platelets showed a gene dosage effect for significantly greater surface-expressed P-selectin, GP IIb/IIIa-bound fibrinogen, and activated GP IIb/IIIa in response to low-dose ADP. Surface expression of GP IIb/IIIa was similar in resting platelets of all 3 genotypes but was significantly greater on Pl(A2,A2) platelets after ADP stimulation (P=0.003 versus Pl(A1,A1); P=0.03 versus Pl(A1,A2)). Pl(A1,A2) platelets were more sensitive to inhibition of aggregation by pharmacologically relevant concentrations of aspirin and abciximab.
CONCLUSIONS: Pl(A2)-positive platelets displayed a lower threshold for activation, and platelets heterozygous for Pl(A) alleles showed increased sensitivity to 2 antiplatelet drugs. These in vitro platelet studies may have relevance for in vivo thrombotic conditions.
Source
Circulation. 2000 Mar 7;101(9):1013-8. doi: 10.1161/01.CIR.101.9.1013